Bioinformatics analysis of miRNA expression profile according to gender in Relapsing-Remitting Multiple Sclerosis patients

Aktaş E., Şahin K. N., Sever T., Özdemir Özgentürk N.

6th International Eurasian Conference on Biological and Chemical Sciences, Ankara, Turkey, 11 - 13 October 2023, pp.1488

  • Publication Type: Conference Paper / Summary Text
  • City: Ankara
  • Country: Turkey
  • Page Numbers: pp.1488
  • Yıldız Technical University Affiliated: Yes


Multiple sclerosis (MS) is the leading cause of neurological disability among adults and affects women three times more than men. Among the subtypes of MS, Remitting-Relapsing MS (RRMS) is the most common, characterized by disease states of remission and relapse, often transitioning to Secondary Progressive MS (SPMS). While the RRMS phase is marked by inflammatory processes, the SPMS phase is marked by neurodegeneration. Scientific evidence indicates that circulating microRNAs (miRNAs) play a significant role in various cellular and physiological functions. miRNAs circulate stably in human blood and are sensitive to processes occurring in the organism. miRNAs have been demonstrated to exert significant effects on MS pathology, with extensive investigations having been conducted and continuing inquiries pursued in this realm. Comprehensive studies on miRNAs exhibiting differing expression levels in male and female patients during the RRMS phase are lacking in the literature. In our study, we employed bioinformatics tools such as GEO2R, Cytoscape, and Morpheus to investigate the differences between remission and relapse disease states of RRMS in male and female subjects. MiRNAs displaying deviant expressions were analysed for both disease states and genders. The results of our investigation reveal that miRNAs with distinct expression levels during the remission and relapse phases of RRMS exhibit gender-specific variations. According to the results that will be obtained from this study, it is believed that specific miRNAs capable of distinguishing MS subtypes can be identified. Furthermore, gender-specific potential biomarkers can be discovered by assessing the shared and non-shared miRNAs between females and males. Additionally, there is potential for the identification of miRNAs that could be implicated in prospective treatment and drug development endeavours.